Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: A randomized, double-blind, phase III study

Supportive Care in Cancer

Volumn 19, Issue 10, 2011, Pages 1609-1617

  Boccia, Ralph V ^a   Gordan, Lucio N ^b   Clark, Gemma ^c   Howell, Julian D ^c   Grunberg, Steven M ^d  

^a Center for Cancer and Blood Disorders   (United States)

^b Gainesville Hematology Oncology Associates   (United States)

^c Clinical Development   (United States)

^d UNIVERSITY OF VERMONT   (United States)

Author keywords

Cancer; Chemotherapy induced nausea and vomiting (CINV); Granisetron; Multi day; Transdermal

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CORTICOSTEROID DERIVATIVE; GRANISETRON;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANOREXIA; APPETITE; APPLICATION SITE PRURITUS; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUSHING; HEADACHE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MEGACOLON; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RETCHING; SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; GRANISETRON; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; VOMITING;

EID: 80052464732     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-0990-y     Document Type: Article

References (21)

1. JD Hainsworth 1992 The use of ondansetron in patients receiving multiple-day cisplatin regimens Semin Oncol 19 48 52 1387250 1:STN:280:DyaK38zns1Gltw%3D%3D
2. PH De Mulder F Roila MG Kris MM Marty 1998 Consensus regarding multiple day and rescue antiemetic therapy Support Care Cancer 6 248 252 9629878 10.1007/s005200050162 (Pubitemid 28213061)
3. Dearnaley DP, Judson I, Root T (2002) Handbook of adult cancer chemotherapy schedules, 2nd edn. Oxon, UK, TMG Healthcare Communications, in collaboration with The Royal Marsden NHS Trust
4. J Herrstedt TC Sigsgaard HA Nielsen J Handberg SW Langer S Ottesen P Dombernowsky 2007 Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy Support Care Cancer 15 417 426 17093916 10.1007/s00520-006-0158-y 1:STN:280: DC%2BD2s3mslyjug%3D%3D (Pubitemid 46697012)
5. RM Navari 2007 Prevention of emesis from multiple-day and high-dose chemotherapy regimens J Natl Compr Canc Netw 5 51 59 17239326 1:CAS:528:DC%2BD1cXmtFygsr8%3D (Pubitemid 46212277)
6. G Lefevre G Sedek SS Jhee MT Leibowitz HL Huang A Enz S Maton L Ereshefsky F Pommier H Schmidli S Appel-Dingemanse 2008 Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients Clin Pharmacol Ther 83 106 114 17522596 10.1038/sj.clpt.6100242 1:CAS:528:DC%2BD2sXhsVylt7bL
7. DT Lowenthal KM Matzek TR MacGregor 1988 Clinical pharmacokinetics of clonidine Clin Pharmacokinet 14 287 310 3293868 10.2165/00003088-198814050-00002 1:STN:280:DyaL1c3ot12mtA%3D%3D
8. L Kraut AA Fauser 2001 Anti-emetics for cancer chemotherapy-induced emesis: potential of alternative delivery systems Drugs 61 1553 1562 11577793 10.2165/00003495-200161110-00003 1:STN:280:DC%2BD3MrjtFKksA%3D%3D (Pubitemid 32905277)
9. K Jordan C Sippel HJ Schmoll 2007 Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations Oncologist 12 1143 1150 17914084 10.1634/theoncologist.12-9-1143 1:CAS:528:DC%2BD2sXht1Krs7rO (Pubitemid 350007026)
10. LH Einhorn SM Grunberg B Rapoport C Rittenberg P Feyer 2010 Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement Support Care Cancer 10.1007/s00520-010-0920-z [Epub ahead of print]
11. J Howell J Smeets HJ Drenth D Gill 2009 Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting J Oncol Pharm Pract 15 223 231 19304880 10.1177/1078155209104063 1:CAS:528:DC%2BC3cXhsVymtbc%3D
12. PJ Hesketh MG Kris SM Grunberg T Beck JD Hainsworth G Harker MS Aapro D Gandara CM Lindley 1997 Proposal for classifying the acute emetogenicity of cancer chemotherapy J Clin Oncol 15 103 109 8996130 1:STN:280: DyaK2s7kvFehsA%3D%3D (Pubitemid 27020563)
13. P Eisenberg J Figueroa-Vadillo R Zamora V Charu J Hajdenberg A Cartmell A Macciocchi S Grunberg 2003 Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron Cancer 98 2473 2482 14635083 10.1002/cncr.11817 1:CAS:528:DC%2BD3sXpvFOrt70%3D (Pubitemid 37466663)
14. R Gralla M Lichinitser S Van der Vegt H Sleeboom J Mezger C Peschel G Tonini R Labianca A Macciocchi M Aapro 2003 Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann Oncol 14 1570 1577 14504060 10.1093/annonc/mdg417 1:STN:280:DC%2BD3svktlKitQ%3D%3D (Pubitemid 37304615)
15. European Medicines Agency (2009) European public assessment report for Aloxi: scientific discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/ aloxi/056305en6.pdf. Accessed March 2010
16. FDA Center for Drug Evaluation and Research (2002) Approval package for palonosetron: statistical review. http://www.accessdata.fda.gov/drugsatfda-docs/ nda/2003/21-372-Alox-Statr.pdf. Accessed March 2010
17. K Jordan A Hinke A Grothey W Voigt D Arnold HH Wolf HJ Schmoll 2007 A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis Support Care Cancer 15 1023 1033 17205281 10.1007/s00520-006-0186-7 1:STN:280:DC%2BD2srgsFSisw%3D%3D (Pubitemid 47340963)
18. International Conference on Harmonisation (1998) Data analysis considerations: Analysis sets. pp 21-27
19. J Handberg V Wessel L Larsen J Herrstedt HH Hansen 1998 Randomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapy Support Care Cancer 6 63 67 9458539 10.1007/s005200050134 1:STN:280:DyaK1c7itVWhsA%3D%3D (Pubitemid 28134049)
20. FM Schnell 2003 Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control Oncologist 8 187 198 12697943 10.1634/theoncologist. 8-2-187 1:CAS:528:DC%2BD3sXjsVOmt7o%3D (Pubitemid 36428284)
21. PR Blower 2003 Granisetron: relating pharmacology to clinical efficacy Support Care Cancer 11 93 100 12560937 (Pubitemid 36733818)